Informations générales (source: ClinicalTrials.gov)
Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4 (ALCINA4)
Interventional
N/A
Institut Curie (Voir sur ClinicalTrials)
mai 2022
juin 2031
30 juillet 2024
Multi-cohort exploratory prospective study. Participation in the ALCINA 4 study does not
change the standard management of the patient, including the treatments administered. A
sampling schedule will be set up for each cohort.
Depending on the clinical context studied and the biomarkers studied and/or sought, the
timing of blood samples will vary between cohorts. There may be up to 4 samples taken per
patient for up to 12 or 18 months. If a specific tumor sample is required, it will be
collected only once during the study.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 04/09/2024 13:49:42 | Contacter | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | 04/09/2024 13:49:28 | Contacter | |||
Critères
Tous
Inclusion Criteria:
- Patient treated for cancer at one of the participating center
- 18 years old or higher
- Signed informed consent form
- Patient not deprived of their liberty or under guardianship (including temporary
guardianship)
- Patient covered by social security scheme
- Patient with no compliance issue (related to geographical, social or psychological
reasons) for study follow up
- Other additional criteria will be defined (defining tumor type and clinical
setting), by cohort
If a biopsy tumor sample is to be taken:
- Tumor considered as accessible by biopsy (at the investigator's discretion).
- Normal blood coagulation tests (if applicable, and in case of a non-superficial
tumor lesion).
- No anticoagulant or antiaggregant treatment for the biopsy.
Exclusion Criteria :
Pregnant and/or breast-feeding women depending on cohort.
- Patient treated for cancer at one of the participating center
- 18 years old or higher
- Signed informed consent form
- Patient not deprived of their liberty or under guardianship (including temporary
guardianship)
- Patient covered by social security scheme
- Patient with no compliance issue (related to geographical, social or psychological
reasons) for study follow up
- Other additional criteria will be defined (defining tumor type and clinical
setting), by cohort
If a biopsy tumor sample is to be taken:
- Tumor considered as accessible by biopsy (at the investigator's discretion).
- Normal blood coagulation tests (if applicable, and in case of a non-superficial
tumor lesion).
- No anticoagulant or antiaggregant treatment for the biopsy.
Exclusion Criteria :
Pregnant and/or breast-feeding women depending on cohort.